About Kedalion Therapeutics
Kedalion Therapeutics is a company focused on the development of innovative ocular delivery platforms in the healthcare sector. The company's main product is a novel topical ocular delivery device, designed to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye, potentially enhancing patient comfort during therapy administration. The company primarily serves the healthcare industry, particularly in the area of ophthalmology. It is based in Menlo Park, California.
Kedalion Therapeutics Patents
Kedalion Therapeutics has filed 18 patents.
Medical equipment, Drug delivery devices, Actuators, Acoustics, Fluid dynamics
Medical equipment, Drug delivery devices, Actuators, Acoustics, Fluid dynamics
Latest Kedalion Therapeutics News
Sep 27, 2023
Ocular Hypertension Treatment Market it Would Grow upto USD 6.5 Billion by 2030 Data Bridge Market research has a newly released expansive study titled “ Ocular Hypertension Treatment Market ” which guarantees you will remain better informed than your competition. This study provides a broader perspective of the marketplace with its comprehensive market insights and analysis which eases survival and success in the market. Data Bridge Market Research analyses a growth rate in the global ocular hypertension treatment market in the forecast period 2023-2030. The expected CAGR of global ocular hypertension treatment market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 5.13 billion in 2022, and it would grow upto USD 6.5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. As per the records of October 2021, World Health Organization on blindness and vision impairment, it is projected that nearly 2.2 billion people face distance or near vision impairment disorders. Eye-related disorders have appeared as a possible potential threat to the populations in all middle-income and industrialized countries. The top causes of vision impairment include uncorrected refractive errors, age-related macular degeneration, cataract, and many others. Market Overview: Ocular hypertension happens when the eye’s pressure (intraocular pressure or IOP) becomes higher than average. It instigates increased eye strain. Glaucoma may be caused by increased pressure than the normal eye pressure. Glaucoma is a type of condition in which eye pressure affects the optic nerve and leads to loss of vision. However, ocular hypertension is not similar to glaucoma. In this condition, the optic nerve looks normal and there are no signs of vision loss. Although, many people having ocular hypertension are at increased risk for glaucoma and are considered “glaucoma suspects.” Drivers Increase in elderly population The global ocular hypertension treatment market is projected to witness a heavy growth rate during the forecast period driven by the factor of an aging population. The growing demand in the global ocular hypertension treatment market is the replication of the rising elderly population, as people aged over 60 years normally develop conditions wherein the eyes have reduced elasticity, affecting the normal functioning. This boost the market growth. Advanced technological advancements Increasing technological advancements associated with the ocular hypertension treatment and diagnostics are boosting the growth of the market. Technologies such as medical imaging, selective laser trabeculoplasty (SLT), visual fields, micro-invasive glaucoma surgery (MIGS), optical coherence tomography (OCT), and progression analysis software will increase patient preference. Moreover, the market size will increase if laser therapies are combined with medications to treat glaucoma as the first-line therapy. This boosts the market growth Opportunities Rising strategic initiatives The strategic initiatives that major key players undertake is projected to increase the market growth. For instance, in June 2022, Novartis Pharmaceuticals Corporation announced the acquisition of Kedalion Therapeutics for its novel AcuStream technology. This acquisition pushed Novartis to boost its ophthalmic product portfolio. In addition to this, in June 2022 Amring Pharmaceuticals Inc. announced that its generic Timolol Maleate Ophthalmic Solution has received approval from the U.S FDA. Timolol Maleate Ophthalmic Solution is a preservative-free solution and is recommended in the treatment of open-angle glaucoma and ocular hypertension. Key players operating in the global ocular hypertension treatment market include: Aerie Pharmaceuticals, Inc. (U.S.) Laboratorios Sophia (Mexico) Neurim Pharmaceuticals LTD (Israel) Bausch Health Companies Inc. (Canada. ), Merck & Co. Inc. (U.S.) The report provides insights on the following pointers: Market Penetration: Comprehensive information on the product portfolios of the top players in the this market Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies Critical Insights Related to This Market Included in the Report: Exclusive graphics and Illustrative SWOT analysis of some of the leading companies in this market Value chain analysis of prominent players in the market Current trends influencing the dynamics of this market across various geographies Recent mergers, acquisitions, collaborations, and partnerships Revenue growth of this industry over the forecast period Marketing strategy study and growth trends Growth driven factor analysis An empirical evaluation of the curve of this market Ancient, Present, and Probable scope of the market from both prospect value and volume Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-ocular-hypertension-treatment-market&Shri Top DBMR Healthcare Reports: An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate. Contact Us:-
Kedalion Therapeutics Frequently Asked Questions (FAQ)
Where is Kedalion Therapeutics's headquarters?
Kedalion Therapeutics's headquarters is located at 1490 O’Brien Drive,, Menlo Park.
What is Kedalion Therapeutics's latest funding round?
Kedalion Therapeutics's latest funding round is Series B.
How much did Kedalion Therapeutics raise?
Kedalion Therapeutics raised a total of $5M.
Who are the investors of Kedalion Therapeutics?
Investors of Kedalion Therapeutics include Novartis and Lagunita BioSciences.
Who are Kedalion Therapeutics's competitors?
Competitors of Kedalion Therapeutics include Nanodropper.
Compare Kedalion Therapeutics to Competitors
Nanodropper is a company focused on healthcare innovation, specifically in the domain of eye care. The company's main product is a volume-reducing adaptor for eyedrop bottles, which reduces the size of the droplets dispensed, minimizing waste and potentially reducing cost and side effects. The company primarily serves the healthcare sector, with a particular emphasis on eye care professionals and patients. It was founded in 2018 and is based in Rochester, Minnesota.
Eyenovia (NASDAQ: EYEN) develops therapeutics on its Microdose Array Print (MAP) platform using technology for progressive myopia, presbyopia, and mydriasis. Its pipeline focuses on the development of micro-therapeutics for glaucoma and other eye diseases. The company was founded in 2014 and is based in New York, New York.